GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (NAS:NSPR) » Definitions » Net Income
中文

InspireMD (InspireMD) Net Income : $-19.92 Mil (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is InspireMD Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. InspireMD's Net Income for the three months ended in Dec. 2023 was $-5.41 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.92 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. InspireMD's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.16.


InspireMD Net Income Historical Data

The historical data trend for InspireMD's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Net Income Chart

InspireMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.04 -10.54 -14.92 -18.49 -19.92

InspireMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.85 -4.26 -5.08 -5.18 -5.41

InspireMD Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

InspireMD's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-19.851+-0.065+0+0
=-19.92

InspireMD's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-5.34+0+0+-0.065
=-5.41

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InspireMD  (NAS:NSPR) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

InspireMD's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


InspireMD Net Income Related Terms

Thank you for viewing the detailed overview of InspireMD's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


InspireMD (InspireMD) Business Description

Traded in Other Exchanges
N/A
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.
Executives
Gary S Roubin director 4300 ROCKMORE RD JACKSON, WYOMING WY 83001
Patrick Verta officer: EVP Clinical/Medical Affairs 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Michael Berman director 735 PALAMAR AVENUE, SUNNYVALE CA 94085
Thomas J Kester director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Paul Stuka director C/O OSIRIS PARTNERS, LLC, ONE LIBERTY SQUARE, 5TH FLOOR, BOSTON MA 02109
Andrea Tommasoli officer: Chief Operating Officer 22, RUE DE LA PLAGE, COLLONGES AU MONT D OR I0 69660
Shane Thomas Gleason officer: VP Global Marketing 18 NORTHAMPTON PL, COTO DE CAZA CA 92679
Kathryn Arnold director 1136 CHESTNUT AVE., WILMETTE IL 60091
Marvin Slosman director, officer: CEO and President 4 MENORAT HAMAOR ST., C/O INSPIREMD, INC., TEL AVIV L3 6744832
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Agustin V Gago officer: EVP, Chief Commercial Officer 256 JERUSALEM AVE, MASSAPEQUA NY 11758
Eric L. Olson officer: VP of Global Sales Operations C/O INSPIREMD, INC., 800 BOYLSTON STREET, 16TH FLOOR, BOSTON MA 02199
Campbell Rogers director C/O INSPIREMD, INC., 800 BOYLSTON STREET, SUITE 16041, BOSTON MA 02199
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Eyal Weinstein director C/O LEOREX LTD., P.O.B. 15067 MATAM, HAIFA L3 31905